OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Nagle on Sequencing Challenges in Multiple Myeloma

October 19th 2020

Sarah Nagle, MD, discusses sequencing challenges in multiple myeloma.

Dr. Maki on the Utility of Tazemetostat in Epithelioid Sarcoma

October 19th 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of tazemetostat in epithelioid sarcoma.

Dr. Brar on the Need to Identify Biomarkers in HCC

October 19th 2020

Gagandeep Brar, MD, discusses the need to identify biomarkers in hepatocellular carcinoma.

Dr. Mesa on the Rationale for the Earlier Use of Ruxolitinib in Myelofibrosis

October 16th 2020

Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.

Dr. Silbermann on the CASTOR Trial in Relapsed/Refractory Myeloma

October 16th 2020

Rebecca Silbermann, MD, MMS, discusses the phase 3 CASTOR trial in relapsed/refractory multiple myeloma.

Dr. McDermott on the Design of the DASL-HiCAP Trial in High-Risk Prostate Cancer

October 16th 2020

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the design of the DASL-HiCAP trial in high-risk prostate cancer.

Dr. O’Regan on the Role of Therapy Escalation in HER2+ Breast Cancer

October 16th 2020

Ruth O’Regan, MD, discusses the role of therapy escalation in HER2-positive breast cancer.

Dr. Pautier on Results of the LMS-02 Trial in Uterine and Soft Tissue Sarcomas

October 16th 2020

Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in uterine and soft tissue leiomyosarcoma.

Dr. Sun on First-Line Treatment Challenges in Gastric Cancer

October 16th 2020

Weijing Sun, MD, FACP, discusses remaining challenges in the first-line treatment of patients with gastric cancer.

Dr. Aggarwal on Investigational Biomarkers in Lung Cancer

October 16th 2020

Charu Aggarwal, MD, MPH, discusses investigational biomarkers in lung cancer.

Dr. Azad on Treatment Considerations in Right- Versus Left-Sided CRC

October 16th 2020

Nilofer Saba Azad, MD, discusses treatment considerations in right- versus left-sided colorectal cancer.

Dr. Marshall on Challenges With Sequencing in CRC

October 15th 2020

John L. Marshall, MD, discusses sequencing challenges in colorectal cancer.

Dr. Siena on the Rationale for the DESTINY-CRC01 in Metastatic CRC

October 15th 2020

Salvatore Siena, MD, discusses the rationale for the phase 2 DESTINY-CRC01 trial in metastatic colorectal cancer.

Dr. Azad on Remaining Challenges in CRC

October 15th 2020

Nilofer Saba Azad, MD, discusses remaining challenges in colorectal cancer.

Dr. Schwartz on Future Research Efforts in Sarcoma

October 15th 2020

Gary K. Schwartz, MD, discusses future research efforts in the field of sarcoma.

Dr. Bose on Current Treatment Options for Essential Thrombocythemia

October 15th 2020

Prithviraj Bose, MD, discusses current treatment options for essential thrombocythemia.

Dr. Mesa on Remaining Challenges Faced in MPN Treatment

October 15th 2020

Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.

Dr. Bhat on the Potential for Time-Limited Combinations in CLL

October 15th 2020

Seema A. Bhat, MD, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia.

Dr. Ma on Developing Novel Agents in BTK Inhibitor–Resistant CLL

October 15th 2020

Shuo Ma, MD, PhD, discusses the need to develop novel agents to treat patients with chronic lymphocytic leukemia who develop resistance to BTK inhibitors.

Dr. Davids on Investigational Doublets and Triplets in CLL

October 15th 2020

Matthew S. Davids, MD, MMSc, discusses investigational doublets and triplets in chronic lymphocytic leukemia.